{"url_path":"/sec/asbp/8-k/2026-07-20/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-033942-index.html","accession_number":"0001493152-26-033942","cik":"0001847345","ticker":"ASBP","issuer_name":"Aspire Biopharma Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-033942-index.html","primary_entity_key":"0001847345","primary_entity_name":"Aspire Biopharma Holdings, Inc."},"word_count":219,"has_tables":true,"body_markdown":"**Item\n8.01 Other Events**\n\n \n\nPursuant\nto requests from holders of the Company’s public warrants (the “Public Warrants”), Aspire Biopharma Holdings, Inc.\n(the “Company”) wanted to clarify the terms of the Company’s public warrants which trade under the symbol “ASPBW”.\nThe Warrants were originally issued on February 23, 2022 in connection with the initial public offering of Power Up Acquisition Corp.\nwhich was the Company’s predecessor. The Warrants had an initial exercise price which was $11.50 per share subject to adjustment\nin certain events including a consolidation of the Company’s outstanding shares. On January 16, 2026, the Company affected a reverse\nstock split of 1 for 30 and on May 11, 2026, the Company effected an additional reverse split of its common stock in a ratio of 40-1.\nAs a result of the two reverse splits, the Warrants now have an exercise price of $13,800 per share and a ratio of 1,200 Warrants to\npurchase one share of common stock.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K\nto be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate:\nJuly 20, 2026\n\n \n\nAspire Biopharma Holdings, Inc.\n \n\n \n \n \n\nBy:\n*/s/ Kraig\nT. Higginson*\n \n\nName:\nKraig T. Higginson\n \n\nTitle:\nChief\nExecutive Officer and Chairman"}